Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by longterm56on Jun 17, 2019 7:33pm

118 Views

Post# 29833650

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Silver lining

Exactly the same for me, Lee430. The longer I hold such an absurd overweighted position the higher the probability something nasty could happen.

Another reason I'm puzzled is that since I have been invested (~3 years) , the only "bad" news was the extension on the FDA approval. Everything else played out as expected (except the sales). Usually good news is matched with SP increase ... so I'm puzzled.

So, what is the next big event we're waiting for ... Europe approval? That's also likely to be a non-mover. Maybe next quarter results? Not likely based on what we hear. We're running low on events to look forward to ...

I think I'm in for a long wait ... again.

-LT

Lee430 wrote: Hopefully this is just a delayed reaction as new investors guided to us from the IR person are working through the new info.

My frustration today lies in the lost opportunity I was hoping for to reduce my seriously overweighed position in Thera before a possible market correction.